You're on your way!
You're being directed to a third-party site to get a quote.
Since 2011, we've helped more than 5 million visitors understand Medicare coverage.
By shopping with third-party insurance agencies, you may be contacted by a licensed insurance agent from an independent agency that is not connected with or endorsed by the federal Medicare program.
These agents/agencies may not offer every plan available in your area. Please contact Medicare.gov or 1-800-Medicare to get information on all options available.
Here’s a look at several changes to Medicare prescription drug coverage taking effect in 2027:
Under the Inflation Reduction Act, Medicare Part D now has a cap on out-of-pocket costs. In 2025, enrollees paid no more than $2,000 in out-of-pocket costs for their covered drugs,1 but that limit is indexed each year. In 2026 it was $2,100,2 and it’s growing to $2,400 for 2027.3
As was the case in 2025 and 2026, enrollees will continue to have the option to spread their drug costs out in equal payments across the year. This could be beneficial to those who might otherwise have to pay the full $2,400 in just the first few months of the year.4
Various other improvements to Medicare Part D benefits (and coverage of drugs under Part B) have been phased in since 2023 as a result of the Inflation Reduction Act. These include $35 insulin, free recommended vaccines, and lower coinsurance costs for certain infusion drugs covered under Medicare Part B. These provisions continue to be in place in 2027.
The Part D prescription drug deductible was a maximum of $615 in 2026,2 and it’s increasing to $700 in 2027.3
Some Part D plans have lower deductibles (or no deductible at all), but no plans can have deductibles that exceed $700 in 2027.
After you pay your deductible, you’ll pay copays (a fixed amount) or coinsurance (a percentage of the cost) for your medications until you’ve spent $2,400 in out-of-pocket costs, including the deductible. After that, drugs covered by your plan will have no out-of-pocket costs for the rest of the year.
It’s important to mention that changes to your Medicare Part D costs can stem from changes in your own prescription needs, changes in your plan’s design, or a plan change that you make during open enrollment (October 15 – December 7). It’s important to carefully compare the various options each year during open enrollment to see how your existing plan – and the other plans available in your area – will cover your specific drugs for the coming year.
This is true whether your Part D coverage is provided by a stand-alone plan or as part of a Medicare Advantage plan. But if you have a Medicare Advantage plan, you’ll also need to consider how the plan and available alternatives cover the rest of your medical needs, in addition to your prescription needs.
(Medicare’s plan comparison tool is useful for determining how each plan will cover your prescription drugs, and what your out-of-pocket costs will be. If in doubt, it’s important to seek assistance from a broker or SHIP counselor, or to call Medicare or the health plan directly.)
The Inflation Reduction Act allowed Medicare to begin price negotiations with drug manufacturers, which previously wasn’t allowed.5 The price negotiations are being phased in over several years, starting in 2026.
Ten drugs – covered by Medicare Part D – were selected for the first round of negotiations: Januvia, Fiasp/NovoLog, Farxiga, Enbrel, Jardiance, Stelara, Xarelto, Eliquis, Entresto, and Imbruvica. Their negotiated prices took effect in January 2026.6
Another 15 drugs have negotiated prices starting in 2027: Ozempic, Rybelsus, Wegovy, Xtandi, Pomalyst, Ibrance, Calquence, Trelegy Ellipta, Ofev, Breo Ellipta, Vraylar, Janumet, Otezla, Linzess, and Xifaxan.7
Enrollees who take medications with newly negotiated prices might find that they pay lower copays or coinsurance when they fill those prescriptions in 2027. And the $2,400 Part D out-of-pocket cap will protect enrollees whose costs would otherwise exceed that limit.
Learn more about the Medicare drug price negotiation program.
Louise Norris is an individual health insurance broker who has been writing about health insurance and health reform since 2006. She has written hundreds of opinions and educational pieces about the Affordable Care Act and Medicare for healthinsurance.org and medicareresources.org.
Footnotes